Clinical Trial

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-07-31; most recent amendment 2023-02-21.
Status change: Recruiting → Active, Not Recruiting 2023-02-21
Status change: Not Yet Recruiting → Recruiting 2020-11-30
Trial Details
NCT Number NCT04499573
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions B-ALL
Enrollment 50 participants
Start Date 2020-07-27
Primary Completion 2022-03-13 (estimated)
Study Completion 2027-03-13 (estimated)
Updated on ClinicalTrials.gov 2023-02-22